Floatz logo

(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone

Sickle Cell Disease

Explore 133 assets in Sickle Cell Disease →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
University of Mississippi Medical Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07369024CT.gov
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
—Recruiting———
NCT04005209CT.gov
Ketamine Infusion for Sickle Cell Pain Crisis
—Withdrawn———
NCT03502421CT.gov
Ketamine Sickle Cell Disease
—Withdrawn———
NCT02801292CT.gov
Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease
—Unknown———
NCT03296345CT.gov
Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
—Completed———
NCT02573714CT.gov
Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises
—Unknown———
NCT02417298CT.gov
Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department
—Terminated———
NCT00595530CT.gov
Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain
—Terminated———
NCT00252122CT.gov
Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Sickle Cell Disease

AssetSponsorPhaseRating
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset)University of Mississippi Medical CenterApprovedB · 61
GlutamineAin Shams UniversityP4BBB
HydroxyureaSt. Jude Children's Research HospitalP4BB
NivestimSt. Jude Children's Research HospitalP4BB
Magnesium MetallicumMedical College of WisconsinP3BB
CrizanlizumabNovartis PharmaceuticalsP4BB
NepentheOman Medical Speciality BoardP4BB
FentanylUniversity College DublinP4BB
ARGTanta UniversityP3BB

+42 more in the Sickle Cell Disease cohort

Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone

IndicationSponsorPhaseRating
Chronic Pain Syndrome—P4BBB · 74
Post-Traumatic Stress Disorder—P4BBB · 74
Depressive Disorder—P4BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Sickle Cell Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-sickle-cell-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →